<Suppliers Price>

Bimekizumab

Names

[ CAS No. ]:
1418205-77-2

[ Name ]:
Bimekizumab

Biological Activity

[Description]:

Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related
Research Areas >> Inflammation/Immunology

[Target]

IL-17A

IL-17F


[In Vitro]

Bimekizumab (10 μg/mL; 1 h) results dual neutralisation of IL-17A and IL-17F, leads to osteocommitment of hPDCs by AS serum is suppressed[1].

[References]

[1]. Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.